Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Sees Significant Drop in Short Interest

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) saw a large decline in short interest in May. As of May 15th, there was short interest totalling 189,600 shares, a decline of 16.8% from the April 30th total of 228,000 shares. Based on an average trading volume of 2,500,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.5% of the company’s stock are short sold.

Biodexa Pharmaceuticals Trading Up 6.5%

Shares of Biodexa Pharmaceuticals stock opened at $1.15 on Tuesday. Biodexa Pharmaceuticals has a 52-week low of $1.01 and a 52-week high of $41.50. The stock has a 50-day simple moving average of $1.38 and a 200-day simple moving average of $3.06.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.